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ABSTRACT
The literature contains robust evidence on the
positive impact of antimicrobial stewardship
programs (ASP) in the inpatient setting. With
national policies shifting toward provisions of
quality health care, the impetus to expand ASP
services becomes an important strategy for
institutions. However data on stewardship
initiatives in other settings are less
characterized. For organizations with an
established ASP team, it is rational to consider
expanding these services to the emergency
department (ED). The ED serves as an interface
between the inpatient and community settings.
It is often the first place where patients present
for medical care, including for common
infections. Challenges inherent to the
fast-paced nature of the environment must be
recognized for successful ASP implementation
in the ED. Based on the current literature, a
combination of strategies for initiating ASP
services in the ED will be described.
Furthermore, common scenarios and
management approaches are proposed for
respiratory tract, skin and soft tissue, and
urinary tract infections. Expansion of ASP
services across the health care continuum may
improve patient outcomes with a potential
associated decrease in health care costs while
preventing adverse effects including the
development of antibiotic resistance.
Keywords: Antibiotic stewardship program;
Emergency department; Emergency medicine;
Implementation; Strategies
INTRODUCTION
Sir Alexander Fleming’s discovery of penicillin
in 1928 marked a momentous event in the
history of modern medicine. In 1945, Sir
Fleming forewarned against overutilization of
antimicrobials during his Nobel Prize
acceptance speech, hinting at the
consequences of antibiotic resistance. Between
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2000 and 2010, antimicrobial utilization
increased by 36% globally [1]. The majority of
the increase occurred in rapidly developing
countries, and the United States ranked third
in the world for total antimicrobial
consumption [1]. As a result of these practices,
there has been a marked increase in
multidrug-resistant (MDR) pathogens,
including methicillin-resistant Staphylococcus
aureus (MRSA) and extended spectrum
beta-lactamase-producing organisms (ESBL) [2].
These resistant isolates are no longer limited to
health care settings, but in recent years have
emerged in the community [2]. Consequently,
the World Health Organization and US Centers
for Disease Control and Prevention (CDC) have
identified antimicrobial resistance as a serious
public health threat [3].
Infections from resistant organisms are
associated with poor patient outcomes with
increased morbidity and mortality [4]. The
management of resistant infections also
contributes to rising health care costs [4].
Furthermore, the rate of eroding antimicrobial
susceptibility patterns has outpaced the rate of
novel antimicrobial drug discovery. In response
to an impending post-antibiotic era, physician
Dale Gerding introduced the concept of
antimicrobial stewardship programs (ASP). The
overarching goals for ASP include optimizing
antimicrobial therapy to enhance patient
safety, reduce inappropriate antimicrobial use,
and preventing antimicrobial resistance. Two
core strategies were developed, forming the
foundation for ASP. Prospective audit with
intervention and feedback involves interaction
and feedback between an infectious diseases
(ID) physician/pharmacist and the ordering
prescriber at the point of order entry [5].
Formulary restriction and preauthorization
establish minimum requirements for
antimicrobial utilization. These standards are
often developed based on local susceptibility
patterns, safety issues, concern for secondary
infections, and affordability (inpatient and
outpatient). In conjunction with supportive
strategies (i.e., education, decision support
services, treatment algorithms), these core
strategies ensure a robust ASP presence. The
literature contains substantial evidence on the
efficacy of these strategies leading to the
development of an endorsed ASP guideline
and inclusion with the National Action Plan
[5, 37].
Despite fewer data on ASP implementation
in other health care settings, ASP efforts should
expand across the care continuum, including
the emergency department (ED). An estimated
142,000 ED visits occur annually secondary to
adverse events associated with antimicrobial
therapy, emphasizing the need for ASP in this
fast-paced environment [6]. The three most
common infections encountered in the ED are
respiratory tract, skin and soft tissue, and
urinary tract infections (UTIs) [6]. These
common infections are managed in both in-
and outpatient settings, and ED practitioners
are involved with establishing empiric and
definitive treatment. As health care legislation
continues to evolve, ED practitioners will be
expected to expand ASP by promoting
adherence to prescribing guidelines,
integrating point of care technologies, and
establishing strategies to avoid antimicrobials
for viral respiratory tract infections or
uncomplicated abscesses.
First, frontline ED practitioners can critically
evaluate patients and determine appropriate
empiric antimicrobial therapy with subsequent
admission, observation, or discharge. Second,
assessments and corresponding treatment plans
are highly valued by their inpatient colleagues.
For admitted patients, implementing changes
to antimicrobial therapy initiated in the ED
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poses challenges for ASP members. Third,
antimicrobial overprescribing in the ED incurs
consequential downstream effects. Therefore,
ED practitioners are uniquely positioned to
implement ASP initiatives and affect change
for the entire organization. ASP members have
the opportunity to engage in dialogue and
incorporate collaborative ASP interventions
with ED practitioners.
Appropriately, May and colleagues [7]
brought attention to ASP implementation in
the ED with a call to action and concept paper
published in 2012. The purpose of this paper is
to summarize the existing literature on various
ED-based ASP processes, with a focus on
managing three commonly encountered
infections. Please note this review is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
ASSESSMENT OF ED CAPACITY
FOR ASP IMPLEMENTATION
Identification of potential barriers to successful
implementation remains a crucial first step for
any new ASP. Inherent to the emergent nature
in the ED, challenges are characterized by high
turnover rates for both patients and
practitioners. The majority (67%) of triaged ED
patients waited\1 h to be seen by a practitioner
[8]. The remaining one-third (35%) of patients
spent between 2 and 4 h from triage to
discharge or admission [8]. Additionally, the
Centers for Medicare and Medicaid Services
(CMS) Core Measure to increase ED
throughput and enhance patient satisfaction
contributes to higher patient turnover rates.
Increasing patient throughput pressures
clinicians to maximize diagnostic efficiency
while maintaining accuracy.
High ED practitioner turnover rates also
challenge ASP implementation and
sustainability. In the case of patients who
bounce back after discharge, this variability in
ED practitioners decreases continuity of care
and may lead to unnecessary changes in
management. The use of validated bedside
scoring tools for risk assessment may
standardize the care provided among ED
practitioners.
In conjunction with increased patient
throughput and higher practitioner turnover
rates, operational challenges are present in the
ED. Rapid decision-making occurs, oftentimes
in the absence of meaningful microbiologic
information. National health care quality
benchmarks, such as CMS Core Measures, may
partly drive the decision-making process for
empiric antimicrobial prescribing. Certainly,
sepsis and other life-threatening cases warrant
appropriate and prompt antimicrobial
administration because it confers a mortality
benefit [9]. However, it should be noted that
antimicrobial selection in the ED has the
potential to determine the treatment course
for both admitted and discharged patients.
Observed in clinical practice, antimicrobial
regimens initiated in the ED are often
continued with reluctance to deescalate even
when another provider has assumed care of the
patient. This approach creates inefficiencies for
the ASP team to enforce inpatient initiatives
and restrictions. Therefore, strategies to
maximize resources that assist in rational and
meaningful decision-making processes are
paramount for ED practitioners. The
combination of diagnostic uncertainty,
compromised patient care through delays in
antimicrobial administration, and predefined
quality expectations perpetuate prevalent
misuse of broad-spectrum antimicrobials in
the ED. After identifying existing and
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potential challenges, the next step involves
garnering support for implementation of
stewardship services in the ED.
POTENTIAL STRATEGIES FOR ASP
IMPLEMENTATION IN THE ED
The following are general antimicrobial
stewardship strategies that transcend across
settings, but can be applied to commonly
encountered scenarios in the ED. A
combination of these strategies is most
effective for developing robust ASP services in
the ED.
Key Players on the ASP ‘‘Dream Team’’
Successful ASP implementation in the ED
depends on gaining support from key opinion
leaders in the emergency medicine department
and administrative leaders in the organization.
Limited resources, reimbursement concerns,
lacking operational infrastructure, and
perception of low efficacy are roadblocks to
ASP presence in the ED [7]. Similar to ASP
implementation in other settings,
circumventing these barriers first requires
buy-in and support from an ED clinician
volunteer who will serve as a liaison on the
ASP committee at the institution. This ED
clinician champion can effectively
communicate new initiatives and resolve
disagreements with their prescriber colleagues.
This individual may buffer the pressure to
overprescribe outside of clinical guidelines as a
response to patient satisfaction. They may also
strengthen other ED prescribers’ comfort in
withholding antibiotics for milder infections
that do not require treatment.
In addition to the ED clinician champion,
the inclusion of a dedicated clinical pharmacist
in the ED adds several values. The benefits
include reducing medication errors, shortening
treatment durations, and decreasing associated
cost of care [10, 11]. Regardless of the ED
coverage model, clinical pharmacists provide
real-time educational feedback and
consultation to practitioners, promote
medication safety by thorough verifications of
drug allergies and comorbidities, communicate
results from microbiology culture and
susceptibility reports, facilitate transitions in
care including comprehensive medication
distribution and reconciliation, and offer
support for non-ID issues such as codes [11].
One example underscores the importance of
medication reconciliation for patients on
antiretroviral therapies. If full integration of a
dedicated ED pharmacist is not feasible for the
organization, it may be worthwhile to have the
ASP pharmacist perform stewardship activities
in some capacity. Sharing the responsibilities
with an internal medicine or medication
reconciliation pharmacist to perform these
functions may also work. Ultimately, the
presence of a clinical pharmacist in the ED
provides several aforementioned benefits to the
organization. These stewardship examples
ensure patients receive appropriate
antimicrobials when they present to the ED.
Real-time follow-up as well as interpretation
of microbiologic culture data is a core
stewardship activity that is particularly
relevant in the ED. Through coordination with
the microbiology laboratory, the clinical
pharmacist can efficiently disseminate results
to prescribers. Dedicated pharmacists who can
proactively review positive cultures and adjust
recommendations are critical to this process
[12, 13]. In particular, this applies to discharged
patients for whom culture data may not result
until 72–96 h post-discharge, often observed in
cases of UTIs. This process decreased the time
between positive culture review and time to
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follow-up with the patient or primary care
provider, if indicated [13]. Furthermore, a
multidisciplinary approach to culture
follow-up has also been associated with a
decrease in return ED visits within 72 h and
hospital readmissions within 30 days [14]. More
than 25% patients required post-discharge
interventions, primarily because of pathogen
non-susceptibility [14]. This study emphasizes
the importance of appropriate antimicrobial
selection while patients are housed in the ED.
Culture follow-up also allows the ED to take
ownership of the care provided to their patients.
Technological Assistance for ASP
The field of rapid diagnostics largely impacts ID
management for admitted patients [15]. Direct
testing from specimen versus culture-based
testing minimizes turnaround times for
organism identification and antimicrobial
susceptibility information. Rapid diagnostics
has the potential to minimize empiric use of
broad-spectrum antimicrobials, thereby
allowing for a thoughtful and targeted
approach to antimicrobial selection. One of
the benefits and the role of rapid molecular
diagnostics in the ED are the immediate results
provided by point-of-care tests (POCT).
Examples include rapid streptococcal antigen
tests and respiratory viral panels. Risk
assessment combined with POCT may enable
ED practitioners to initiate more directed,
narrow-spectrum antimicrobial therapy. POCT
can also guide appropriate antimicrobial
selection for discharge of less serious
infections that do not require admission.
These tests may reduce overall antibiotic use
and facilitate earlier changes in antibiotic
regimens for certain infections [16]. Despite
limited widespread acceptance of POCTs in the
ED, primarily because of cost and potential
laboratory workflow constraints, research and
development in rapid diagnostics continues to
grow. The possibility of individualized care for
all patients who present to the ED remains a
promising prospect in the near future. In
general, these tests are most useful when used
appropriately with expert interpretations.
In the age of electronic health records (EHR),
clinical decision support (CDS) may effectively
deliver pertinent information to ED
practitioners at the point of care. This strategy
relies on an informatics team and a sustainable
technological infrastructure. Ideally, the
information should be concise to minimize
alert fatigue and information overload.
Features should incorporate relevant patient
data (e.g., drug allergies, previous culture
results, contact precautions, current renal
function) aligned with current evidence-based
and institutional-specific recommendations [7].
With federal mandates on EHR
implementation, CDS is an area with potential
growth and high impact for ASP interventions.
Prior to broad implementation of EHR, effective
CDS programs have been associated with
12–14% reduction in antimicrobial
prescriptions [40].
ED-Specific Information
Antimicrobial order forms or order sets, clinical
pathways, and an ED-specific antibiogram, if
feasible, are examples of resources that may
assist ED prescribers during their
decision-making process [7].
Order forms and sets are intended to guide a
prescriber at the point of electronic order entry.
Potential messages that appear with an order
may include best practice alerts (BPA), criteria
for use with restricted agents, and associated
monitoring parameters for specific drugs.
Examples are antimicrobial components for a
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sepsis protocol order set or an antiretroviral
panel alerting prescribers that medication
reconciliation is needed for an admitted
patient. These order forms may prompt ED
practitioners to consult ID and/or facilitate
communications with the ED or ID
pharmacists.
Evidence-based clinical pathways and
algorithms may potentially shape prescribing
practices and ensure consistency among
rotating ED practitioners. After approval from
the Pharmacy and Therapeutics (P&T)
Committee, the pathways should be available
on the intranet for easy retrieval by all staff. The
information should target commonly
encountered infections in the ED such as
community-acquired pneumonia (CAP), UTI,
and Clostridium difficile infection. It may be
beneficial to have recurring educational sessions
or grand rounds with ED prescribers to further
enforce these pathways. This promotes dialogue
and the exchange of ideas while allowing for
valuable visibility of the ED clinical pharmacist.
Integrating pharmacy students and residents
into this educational process provides them
with experiences offering in-service
presentations to an interdisciplinary group.
Lastly, creating an ED-specific antibiogram
based on ED isolates may be useful for tracking
resistance in community and health care
settings. This entails collaborating closely with
the microbiology department to generate this
information. Similar to clinical pathways, the
antibiogram should be posted to the intranet.
Though it is a powerful tool, routine education
and dissemination of information to house staff
is necessary for effective interpretation of the
antibiogram. A clinical pharmacist in the ED
can facilitate these educational and interpretive
processes. They can guide prescribers on
selection of an appropriate empiric
antimicrobial agent, incorporating
susceptibility data generated by the
antibiogram.
ED MANAGEMENT APPROACHES
FOR THREE COMMON INFECTIONS
Respiratory tract, skin and soft tissue, and
urinary tract are the three most common
infections encountered in the ED [6].
Therefore, it is important to highlight
potential treatment strategies and
opportunities for stewardship initiatives for
these three infections.
Acute Respiratory Tract Infections
Evidence for antimicrobial overprescribing has
been well established for acute respiratory tract
infection (ARTI) ambulatory treatment, owing
to fear of patient complaints and dissatisfaction.
Donnelly et al. characterized antibiotic
utilization in pediatric and adult patients
receiving care for ARTI in the ED from 2001 to
2010 using National Hospital Ambulatory
Medical Care Survey data. ARTIs account for
nearly 12% of all ambulatory care visits
annually [17]. Nasopharyngitis, bronchitis or
bronchiolitis, viral pneumonia, and influenza
were identified as not requiring antibiotics.
Expectedly, the use of antibiotics in viral
illnesses has not been shown to improve
patient outcomes. However, more than half
(61%) of ARTI cases with viral etiologies
inappropriately received an antibiotic [17].
Further, Kronman et al. [39] estimated
bacterial prevalence to be 27.4% among
common ARTIs. When assessing antimicrobial
prescribing frequencies, health care providers
may have inadvertently prescribed 11.4 million
antimicrobial courses. These data highlight the
need for integrating strategies that minimize
overtreatment (i.e., watch-and-wait strategies,
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contingency antimicrobial prescriptions, or
rapid diagnostics tools).
Ong et al. [18] surveyed ED physicians and
patients at ten EDs based in academic medical
centers in the US. They sought to characterize
prescribing practices as well as patient
expectations and satisfaction. The study
population included pediatric and adult
patients who had a single diagnosis of
uncomplicated acute bronchitis or upper RTI.
The results are consistent with the findings
previously reported by Donnelly et al. ED
physicians inappropriately prescribed
antibiotics for about two of every three (68%)
patients with acute bronchitis and about one of
every ten (9%) patients with upper RTI [18].
Moreover, physicians prescribed antibiotics
when they believed patients were expecting
them. However, these physicians were only able
to accurately identify true patient expectations
in about a quarter of patients. Additionally, the
receipt of antibiotics was not associated with
patient satisfaction. In fact, patients reported
greater satisfaction when they had a better
understanding of their illness. This message
remains the mainstay for the CDC’s Get Smart:
Know When Antibiotics Work campaign. In this
national campaign, the use of viral illness
prescription pads as a patient education tool
to explain supportive care measures can
increase patient satisfaction.
Consequently, Ong et al. [18] illustrated how
physicians’ misperception of patient
expectations can lead to overprescribing of
antibiotics. Additionally, rates of antibiotic
prescribing were similar across all ED settings,
whether academic or community based. ED
physicians often cited the presence of green or
bloody phlegm as a factor for prescribing
antibiotics [19]. However, data are lacking to
indicate this is due to a bacterial infection [19].
This may represent potential educational
interventions. Incorporation of order forms
and clinical pathways may also provide
prescribing guidance. Lastly, technology such
as rapid diagnostics with respiratory viral panels
may also play a substantial role in decreasing
inappropriate antibiotic use in the ED. An
analysis by Blaschke and colleagues [38]
identified a reduction in ancillary testing (i.e.,
cultures, chest radiographs) and antibiotic
prescriptions when integrating rapid influenza
testing into practice. In contrast, there was a
significant increase in anti-influenza therapy.
These data highlight the potential for
identifying causative organisms associated
with RTI and minimize overtreatment.
In addition to rapid diagnostics and bedside
scoring tools, several studies report the use of
procalcitonin (PCT) to differentiate between
infectious versus noninfectious inflammatory
conditions [20]. PCT is a precursor peptide to
the hormone calcitonin. It becomes acutely
elevated in bacterial infections, but rapidly
decreases during clinical recovery [15].
Compared with other inflammatory
biomarkers, PCT has demonstrated superior
diagnostic accuracy when compared to
C-reactive protein [21, 22]. The interest in
utilizing PCT to guide antibiotic therapy has
been evaluated for both ARTI and sepsis across
multiple care settings.
Schuetz et al. [23] performed a meta-analysis
examining the safety of PCT algorithms to
guide antibiotic initiation and treatment
duration in patients with ARTI across multiple
care settings. The authors concluded that PCT
algorithms effectively reduced overall antibiotic
exposure in patients by 50%, from 8 to 4 days.
They did not observe an increase in mortality or
treatment failure rates. Additionally, the use of
PCT in the ED differentiated congestive heart
failure versus ARTI resulted in a reduction in
adverse events and antimicrobial consumption
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[24]. Studies supporting the use of PCT in other
ARTI include chronic obstructive pulmonary
disease exacerbations and CAP [25–27].
Consistent with data from the meta-analysis,
these studies highlighted a reduction in
antibiotic exposure. Challenges to widespread
implementation of PCT-based algorithms may
include the cost and logistical workflow.
However, incorporation of PCT testing in the
ED may be an effective strategy to reduce
antimicrobial misuse for ARTI.
Skin and Soft Tissue Infections
Despite evolving terminology for skin and soft
tissue infections (SSTI) throughout the years,
the incidence has risen in the past decade [6].
The spread of community-acquired MRSA
(CA-MRSA) infections may have contributed to
the rise along with increases in resource
utilization [28]. An analysis of ED prescribing
patterns for skin infections conducted between
the years 2007 and 2010 revealed a stable rate of
ED visits, but noted an increasing rate of
anti-CA-MRSA antibiotics for skin infections
[28]. Furthermore, patients were frequently
either overtreated with combination therapy
for cellulitis (included agents active against
CA-MRSA) or received unnecessary therapy
following incision and drainage (I&D) of
uncomplicated abscesses. In contrast, when
antimicrobial therapy was warranted for the
treatment of purulent cellulitis, 16% of patients
failed to receive therapy active against
CA-MRSA. These findings highlight the
importance of proper wound classification and
risk stratification in patients with acute
bacterial skin and skin structure infections
(ABSSSIs).
Current recommendations for skin and skin
structure infections from the Infectious Diseases
Society of America (IDSA) suggest that skin
abscesses do not require antibiotic treatment
post successful I&D [29]. The guidelines also
recommend the use of agents effective against
streptococci for nonpurulent cellulitis.
However, these recommendations are rarely
integrated into clinical practice, and patients
are often overtreated for simpler skin infections
[28]. Another situation that supports the need
for an ED-based ASP service is the frivolous
administration of vancomycin in the ED.
Mueller et al. [30] reported in their
single-center study that 68% of patients
received one-time doses of vancomycin prior
to discharge, whereby 73% of these patients
were under-dosed with\15 mg per kg of body
weight. This study highlights the real possibility
of developing resistance if these prescribing
behaviors are not addressed.
Unfortunately, these patients typically
present to the ED or another ambulatory clinic
as their initial point of entry into the health
care system, yet the 2014 IDSA update did not
address management issues specific to the ED.
Appropriately, a best practice guideline for the
management of skin infections has been
outlined specifically for ED practitioners [31].
The treatment approach is to risk stratify based
on disease severity and ensure patients receive
appropriate levels of care (e.g., emergent
surgical interventions for severe sepsis and
necrotizing fasciitis).
For low-risk patients who can be managed in
an outpatient setting, the best practice
guideline divided the group into nonpurulent
versus purulent cellulitis [31]. Consistent with
the IDSA guidelines, patients evaluated to have
nonpurulent cellulitis can be treated with
non-MRSA active oral antibiotics and
discharged. Patients with purulent cellulitis
should be covered with MRSA-active oral
antibiotics and discharged. Conversely,
patients requiring intravenous antibiotics were
S46 Infect Dis Ther (2015) 4 (Suppl 1):S39–S50
further stratified to those eligible for outpatient
parenteral antimicrobial therapy (OPAT) based
on the presence of comorbid conditions (e.g.,
diabetes mellitus, vascular disease). The recent
approvals of long-acting lipoglycopeptide
agents such as dalbavancin and oritavancin,
which possess activity against gram-positive
organisms including MRSA, may play a larger
role in OPAT clinics. With these newer agents,
the treatment paradigm for skin infections
diverts stable patients with milder infections
away from admission. Therefore, ED
stewardship strategies should focus on a
comprehensive and validated process to
determine illness severity and risk stratification
for skin infections.
Urinary Tract Infections
Similar to skin infections, the use of
broad-spectrum antimicrobials extends to UTI
treatment as well. IDSA guidelines state that
asymptomatic bacteriuria (ASB) does not
require antibiotic treatment [32]. UTI
diagnosis based on a urinalysis (UA) or
dipstick alone in the absence of symptoms
leads to overuse of antibiotics [33]. Often
observed in clinical practice, empiric UTI
treatment with a broad-spectrum agent such as
a fluoroquinolone is frequently initiated based
on an improperly collected UA in the ED. Pallin
et al. [33] reported that 58% of patients failed to
receive instructions on urine sample collection,
resulting in only 6% of patients performing the
correct midstream, clean-catch technique. In
addition, according to current guidelines, if
local resistance rates for fluoroquinolone
exceed 10% for common uropathogens such as
Escherichia coli, then oral agents such as
ciprofloxacin and levofloxacin are no longer
recommended for empiric uncomplicated UTI
treatment [34]. Considerations of these
ecological effects also apply to
trimethoprim-sulfamethoxazole (TMP-SMX). If
resistance rates for uropathogens exceed 20%,
TMP-SMX is no longer a recommended first-line
option for uncomplicated cystitis, leaving
clinicians with older agents such as
nitrofurantoin and fosfomycin.
Despite these recommendations, guideline
adherence is difficult in the ED without
guidance from a dedicated pharmacist or ID
specialist. Overtreatment of ASB, especially with
fluoroquinolones, generates more collateral
damage including C. difficile infections. In a
recent study evaluating adherence rates to
uncomplicated UTI guidelines in an ED
setting, Hecker et al. [35] successfully
implemented a UTI electronic order set with
corresponding audit and feedback
interventional periods. The study concluded
that guided order sets accompanied with audit
and feedback successfully reduced
fluoroquinolone prescriptions for
uncomplicated cystitis from 44% at baseline to
13% after the intervention period.
In another study conducted at an academic
tertiary care hospital in Canada, the authors
found that implementation of a best practice
algorithm reduced empiric ciprofloxacin use for
uncomplicated UTIs from 32% to 11% [36]. The
interventions included monthly educational
presentations to the ED practitioners. The
eroding susceptibility patterns for
fluoroquinolones were highlighted with an
in-depth discussion on the adverse effects
associated with this class. These materials were
disseminated in the ED as well as the
institution’s intranet. Although this strategy is
more labor intensive, it is effective and could be
implemented if resources are available
including rotation students and/or residents.
From a stewardship standpoint, CDS plays a
large role in curbing inappropriate
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broad-spectrum antimicrobial use or
overtreatment. Combined with routine
discussions regarding other treatment options
such as oral beta-lactams (cephalexin) and older
agents for patients with optimal renal function
(nitrofurantoin), these strategies may steer
prescribing practices away from the
fluoroquinolones.
Another role for intervention entails culture
data follow-up for discharged patients. For
identified bug-drug mismatches (e.g., a patient
was prescribed an antibiotic on discharge and
subsequent susceptibility results identified the
organism is resistant to that agent), the
pharmacist is alerted to communicate
information directly to the patient or primary
care provider. The reconciliation process may
involve patient assessment or the need for a
new prescription. If these alerts are addressed in
a timely manner, they may avert a potential
readmission. These endeavors align with the
overall health care goal of providing quality
care while keeping costs at bay.
CONCLUSION
The ED offers a myriad of opportunities for
creative antimicrobial stewardship
interventions that could affect change across
the care continuum. Antibiotics prescribed in
the ED have far-reaching consequences
downstream. Therefore, attention and
resources need to be shifted to this setting.
Inherent to the fast-paced nature of this
environment, multiple ED-specific challenges
exist. The challenges can be circumvented
through various strategies to affect changes.
Successful ASP implementation requires a
collective and multidisciplinary effort. Ideally,
an ED clinician champion proactively engaged
with the ASP committee is the crucial step to
initiate stewardship directives. Initiatives can be
targeted at common infections: respiratory
tract, skin, and UTIs. Ultimately, through
provision of ASP services in the ED,
prescribing practices may shift toward more
rational and thoughtful decision-making. The
overall goal is to provide improved care to our
patients efficiently and effectively. More data
capturing stewardship strategies in the ED are
needed.
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